Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

NCT06616961 on ClinicalTrials.gov · last registry update 2024-09-27

Registered but never opened — and the completion date on file, February 2025, has already passed. Its estimated completion date, February 2025, has passed with no update to the record. Primary outcome, as filed: Body Weight (kg). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Popular Medical College Hospital
Sponsor type: Other
Enrollment: 480
Started: 2024-11-01
Primary completion: 2025-02 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body Weight (kg)

Conditions studied

Obesity · Type 2 Diabetes Mellitus (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.